VAERS Explorer
Back to explore

Report #2864442

Received Oct 8, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex
Unknown
Age
Age unknown
State
OH
Recovered
Unknown
Vaccinated
—
Onset
—
Days to onset
—
Hospital days
—

Vaccines (1)

TypeNameManufacturerDoseLotRoute / Site
DTAPDTAP (NO BRAND NAME)UNKNOWN MANUFACTURERUNK—OT

Symptoms (2)

No adverse eventProduct storage error

Symptom narrative

Temperature excursion due to human error, Max/low temperature reached 560F for 4 hours, 32.20F for 2.25 hours, 48.80F for 0.75 hours and it was recommended to revaccinate with no reported adverse event; Initial information received on 24-Sep-2025 regarding an unsolicited valid non-serious case received from a physician. This case involves Adult and unknown gender patient who received Diphtheria, Tetanus And Acellular Pertussis Vaccine excursion due to human error, max/low temperature reached 560f for 4 hours, 32.20f for 2.25 hours, 48.80f for 0.75 hours and it was recommended to revaccinate with no reported adverse event. The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. On an unknown date, the patient received an unknown dose of suspect Diphtheria, Tetanus And Acellular Pertussis Vaccine produced by unknown manufacturer (lot number, strength, expiry date and formulation-unknown) via intramuscular route in unknown administration site for prophylactic vaccination (Immunization) where max/low temperature reached 560f for 4 hours, 32.20f for 2.25 hours, 48.80f for 0.75 hours and it was recommended to revaccinate with no reported adverse event (poor quality product administered) (latency-same day). Information on the batch number was requested corresponding to the one at time of event occurrence. Action taken was not applicable. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.